Business Wire

MERZ-AESTHETICS

5.11.2020 09:32:12 CET | Business Wire | Press release

Share
Merz Aesthetics to Sponsor and Participate in First Fully Virtual Medical Aesthetics Congress AMWC Global 2020

Merz Aesthetics, a global leader in medical aesthetics, today announced the presentation of data from its medical aesthetics portfolio at the 18th edition of the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place virtually as “AMWC Global 2020, The Virtual Edition”, to be held from Thursday, November 5 to Saturday, November 7, 2020. Merz Aesthetics is an elite sponsor of the global industry congress.

“We are proud to continue our commitment to the medical aesthetics industry by sponsoring this virtual meeting. We are looking forward to sharing data on the Merz Aesthetics portfolio, engage with our customers and partners and present Merz Aesthetics in a new innovative format. It’s time to think differently to keep the momentum of the industry,” said Frank Brandt-Pollmann, President EMEA, Merz Aesthetics.

In addition to the presentations listed below, Merz Aesthetics is sponsoring two symposium events to be held over the course of the meeting and led by renowned medical aesthetic experts:

“The Skin You Are In – Collagen Expert Session” to be held on Friday, November 6, 15:15h – 16:15h CET. The session will include injection videos and insights from renowned international experts:

  • Dr. Gabriela Casabona – Aesthetic Physician, Spain
  • Dr. Jani van Loghem – Aesthetic Physician, The Netherlands
  • Professor Yana A. Yutskovskaya – Dermatologist, Russia

“conFRONT every LINE! – Upper Face Rejuvenation” to be held on Saturday, November 7, 12:30h – 13:30h CET. The session will include injection videos and insights from renowned international experts:

  • Dr. Tatjana Pavicic – Dermatologist, Germany
  • Dr. Thomas Rappl – Dermatologist, Austria

Oral Presentations
Gabriela Casabona: ‘CaHA as a Biostimulator’ (Evolution of Regenerative Aesthetics Where are We Now Session); Thursday, November 5, 13:30-15:30h CET, AMWC Stream 2*

Dr. Carla Pecora: ‘Botulinum Toxin Injection: Customized Eyebrow Reshape and Positioning, with an Individualized Approach’ (Forehead Treatment and Importance of the Eyebrow Line Session); Thursday, November 5, 16:30-18:30h CET, AMWC Stream 1*

Dr. Daria Voropai: ‘Midface Dilemmas: How Individual Approaches Require a Multiple Tissue Plane Approach and How Ultrasound, Tactile Feedback, Visual Cues Help Us to Achieve This’ (Cheeks: Fillers, Threads of Both? Session); Friday, November 6, 16:30-18:30h CET, AMWC Stream 2 *

Dr. Kate Goldie: ‘Redefining the Art of the Lip’ (Lips and Perioral Rejuvenation Session); Saturday, November 7th, 14:00-16:00h CET, AMWC Stream 2 *

Virtual E-Poster Presentations
Virtual posters will be available for viewing for the duration of the congress.

Botulinum Toxin

  • IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines. Martina Kerscher, MD - Germany, Sabrina Fabi, MD – USA, Tanja Fischer, MD PhD – Germany, Michael Gold, MD – USA, John Joseph, MD – USA, Welf Prager, MD – Germany, Berthold Rzany, MD ScM – Germany, Steve Yoelin, MD – USA, Susanna Roll, Dr. med – Germany, Gudrun Klein, PhD – Germany, Corey Maas, MD PhD – USA.
  • Decreased Therapeutic Effect Over Time Amongst Botulinum Toxin Type A Agents. Rashid Kazerooni – Merz North America, USA.
  • Neurotoxin Impurities: A Review of Threats to Efficacy. Je-Young Park, MD - USA, Owen Sunga, MD, MSc – Singapore, Rungsima Wanitphakdeedecha, MD, MA, MSc – Thailand, Jürgen Frevert, PhD - Germany.

Belotero®

  • Safety of Cohesive Polydensified Matrix Cross-Linked Hyaluronic Acid Volumizing Gel in Temporal Hollows and Cheeks: A Prospective, Open-Label, Post-Market Study. Tatjana Pavicic, MD –Germany; Gerhard Sattler, MD – Germany, Welf Prager, MD – Germany, Tanja Fischer, MD PhD – Germany, Gerd Gauglitz, MD – Germany, Matthias Hofmann, PhD - Germany; Hanna Dersch – Germany; Shahbaz Riaz, PharmD – USA, Martina Kerscher, MD – Germany.
  • Hydration Effect of a Revitalizing CPM® Cross-Linked Hyaluronic Acid Gel Containing Glycerol. Kay Marquardt, Sabine Falk, Matthias Hofmann, Jeannette Simon, Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.

Radiesse®

  • CaHA microspheres remodel collagen networks leading to improved skin quality and reveal new treatment possibilities. Gabriela Casabona, MD – Spain, Bartosch Nowag, Daniela Schäfer, Davide Greco, Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany
  • Combination of Calcium Hydroxylapatite Diluted with Normal Saline and Microfocused Ultrasound with Visualization for Skin Tightening. Yana Alexandrovna Yutskovskaya, MD - Russia, Anna Daniilovna Sergeeva, MD – Russia, Evgeniya Altarovna Kogan, MD PhD – Russia.*

Ultherapy®

  • Optimizing Patient Outcomes through a Customized Approach of Microfocused Ultrasound with Visualization Treatments: Consensus Guidelines from an Expert Panel. Sabrina G. Fabi, MD - USA, John Joseph, MD - USA, Julia Sevi, MD PhD - UK, Jeremy B. Green, MD - USA, Jennifer Deaver Peterson, MD – USA.

*Merz-supported Investigator Initiated Trial

About Merz Aesthetics
At Merz Aesthetics, we are a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with the highest standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with locations in 32 countries worldwide. Merz Aesthetics is part of Merz Group, a family owned company founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com.

Copyright © 2020 Merz Pharmaceuticals GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release

Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM

BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ

Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release

The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College

Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release

As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi

ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release

Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye